Our Leadership
Aprecia, the 3DP pharmaceutical company, is a privately held pharmaceutical technology company led by a seasoned, highly motivated team of accomplished individuals who have been dedicated to the advancement of pharmaceuticals.
The Team
Chairman
E. Thomas Arington
Mr. Arington has served as a member of the Aprecia Pharmaceuticals Board of Directors since 2010 and as Chairman of the Board since 2011. His vision for three-dimensional printing in pharmaceuticals spans more than 20 years. Mr. Arington has spent his lifetime in the pharmaceutical industry, significantly contributing to the advancement of pharmaceuticals in multiple companies and roles, including:
- Founder and Chairman of Prasco
- Former Chairman and CEO of Duramed Pharmaceuticals, Inc.
- Former Chairman and CEO of MarketMaster
- 17 years with Lederle, including senior management positions
President and Chief Operating Officer
Kyle Smith
Kyle Smith was named President and Chief Operating Officer in October 2021. Mr. Smith is a 10-year veteran with Aprecia and most recently served as Vice President of Operations. Mr. Smith is responsible for leading day-to-day business activities. Mr. Smith holds a Master of Business Administration degree from Miami University, and a Bachelor of Science in Chemical Engineering from Georgia Institute of Technology.
Chief Commercial Officer
Andrew Karazim
Andrew Karazim leads Aprecia’s commercialization efforts as the Chief Commercial Officer. He brings over 25 years of pharmaceutical and biotechnology experience. Andrew is an enterprise leader with broad experience across sales, marketing and market access.
Over his 25-year career in the industry, Karazim held leadership roles at Lilly, Abbott and Kaleo. Most recently, he was the Head of Market Access at biotech start up Kaleo. Prior to that, he served as the General Manager for Abbott Diabetes Care. Karazim spent the first 22 years of his career at Lilly in a variety of Commercial leadership positions in the US and globally.
Andrew earned his bachelor’s degree from Yale University and completed his MBA in pharmaceutical marketing from Saint Joseph’s University in Philadelphia.
SVP Scientific Affairs
Kathi Rinesmith
Mrs. Rinesmith serves as Aprecia’s Senior Vice President of Scientific Affairs, where she leads the company’s regulatory strategy, objectives, policies, and programs pertaining to the company’s marketed and pipeline products. Her more than 30 years of experience spans the development and registration of pharmaceutical products from early-to late-stage product development, during which she has demonstrated success leading sponsor teams at FDA meetings and through the registration review process with the FDA for new product approvals. In addition, she’s been responsible for product life-cycle management, fulfillment of product post-approval reporting obligations and global pharmacovigilance for commercial products as well as those in development. She has also contributed toward industry initiatives to develop science-based approaches to regulation by serving on a past Product Quality Research Institute (PQRI) Packaging Committee, by serving on a USP Expert Committee for Pharmaceutical Dosage Forms for a 5-year term and by providing industry feedback on draft FDA guidance documents. Previously, Mrs. Rinesmith held senior executive product development and regulatory roles at:
- Camargo Pharmaceutical Services
- Prasco Laboratories
- Barr Labs
- Duramed Pharmaceuticals
Chief Financial Officer and SVP of Business Operations
Mike Rohlfs
Mr. Rohlfs has served as Aprecia’s Chief Financial Officer since July 2013 and brings over 20 years of experience in the pharmaceutical industry. Mr. Rohlfs’ career has been focused in the areas of strategic planning, finance, business operations and business analytics while serving in progressive management and leadership roles including:
- Vice President of Business Development Services at Prasco Laboratories
- Plant Controller at Barr Laboratories
- Director of Planning & Budget at Duramed Pharmaceuticals